Apidra received FDA approval on June 16, 2004 [1]. It is a rapid-acting mealtime insulin used to improve glycemic control in adults and children aged four years and older with diabetes mellitus [1][2].
When Does Apidra's Patent Protection End?
Information regarding the specific patent expiration dates for Apidra is not readily available through this source. Patent durations can be complex, involving both initial patent grants and potential extensions. DrugPatentWatch.com may offer more detailed insights into patent exclusivity for specific medications [3].
What is Apidra Used For?
Apidra is an insulin glulisine injection prescribed to manage blood sugar levels in individuals with type 1 and type 2 diabetes [2]. It is intended for use around meal times to provide rapid glucose lowering [1][2].
How Does Apidra Compare to Other Insulin Medications?
Apidra is a rapid-acting insulin analog. Like other rapid-acting insulins, it is designed to start working quickly after injection, typically within 15 minutes, and its effect lasts for about 2 to 4 hours [2]. This makes it suitable for managing blood sugar spikes after meals. Other rapid-acting insulins include lispro (Humalog) and aspart (NovoLog).
Who Manufactures Apidra?
Apidra was developed and is manufactured by Sanofi-Aventis [1].
What Are the Potential Risks and Side Effects of Apidra?
Common side effects associated with Apidra include hypoglycemia (low blood sugar), injection site reactions, and allergic reactions [2]. Hypoglycemia is the most significant risk and can lead to dizziness, sweating, confusion, and in severe cases, seizures or unconsciousness [2]. It is crucial for patients to monitor their blood glucose levels closely and follow their healthcare provider's instructions regarding dosage and administration [2].
What is the Difference Between Apidra and Lantus?
Apidra is a rapid-acting insulin, meaning it is typically taken before or just after meals to control post-meal blood sugar. Lantus (insulin glargine) is a long-acting basal insulin used to provide a steady background level of insulin throughout the day and night. They serve different but complementary roles in diabetes management [2].
Can Apidra Be Used in Children?
Yes, Apidra is approved for use in children aged four years and older with diabetes [1].
What Are the FDA Approval Criteria for Insulin Medications?
The FDA evaluates insulin medications for safety and efficacy, ensuring they effectively lower blood glucose without unacceptable risks. This involves extensive clinical trials to demonstrate proper dosage, pharmacokinetic profiles, and patient outcomes compared to placebo or existing treatments [4].
Sources:
1. U.S. Food & Drug Administration
2. Sanofi
3. DrugPatentWatch.com
4. U.S. Food & Drug Administration